Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Hansen, Barbara C ^a   Tigno, Xenia T ^a   Bénardeau, Agnes ^b   Meyer, Markus ^b   Sebokova, Elena ^b   Mizrahi, Jacques ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALEGLITAZAR; APOLIPOPROTEIN A1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A2; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; RHESUS MONKEY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; BLOOD; DISEASE MODEL; DRUG POTENTIATION; EATING; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MACACA MULATTA; METABOLISM; OBESITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TIME;

ADMINISTRATION, ORAL; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; EATING; HEMOGLOBIN A, GLYCOSYLATED; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MACACA MULATTA; MALE; METABOLIC SYNDROME X; OBESITY; OXAZOLES; PPAR ALPHA; PPAR GAMMA; PREDIABETIC STATE; THIOPHENES; TIME FACTORS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 78651560212     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-7     Document Type: Article

References (36)

1. Fact Sheet No. 312 - Diabetes. , http://www.who.int/mediacentre/factsheets/fs312/en/
2. American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl 1):S12-S54. American Diabetes Association.
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28:2375-2414. 10.1093/eurheartj/ehm316, 17726041.
4. Bodkin NL, Metzger BL, Hansen BC. Hepatic glucose production and insulin sensitivity preceding diabetes in monkeys. Am J Physiol 1989, 256:E676-E681.
5. Clark A, de Koning EJ, Hattersley AT, Hansen BC, Yajnik CS, Poulton J. Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract 1995, 28(Suppl):S39-S47. 10.1016/0168-8227(95)01075-O, 8529518.
6. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986, 29:713-719. 10.1007/BF00870281, 3542671.
7. Hansen BC, Bodkin NL. Beta-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol 1990, 259:R612-R617.
8. Hansen BC, Striffler JS, Bodkin NL. Decreased hepatic insulin extraction precedes overt noninsulin dependent (type II) diabetes in obese monkeys. Obes Res 1993, 1:252-260.
9. Hansen BC. Primate models of type 2 diabetes. Diabetes Mellitus: A Fundamental and Clinical Text 2004, 1059-1074. Philadelphia: Lippincott, Williams & Wilkins, LeRoith D, Olefsky JM, Taylor SI, 3.
10. Tigno XT, Hansen BC. The rhesus monkey (Macaca mulatta) manifests all features of human type 2 diabetes. Animal Models of Diabetes: Frontiers in Research 2007, 251-270. New York: CRC Press, Shafrir E, 2., http://www.crcpress.com/product/isbn/9780849395345
11. Hansen BC. Chronomics of the metabolic syndrome. The Metabolic Syndrome: Epidemiology, Clinical Treatment, and Underlying Mechanisms 2008, 373-386. Totowa, New Jersey: Humana Press, Hansen BC, Bray GA.
12. Ding SY, Tigno XT, Hansen BC. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. Metabolism 2007, 56:838-846. 10.1016/j.metabol.2007.01.015, 17512318.
13. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and Morbidity in laboratory-maintained rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci 2003, 58(3):212-219.
14. Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor α/γ dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 2007, 56:1334-1339. 10.1016/j.metabol.2007.05.019, 17884441.
15. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994, 43:204-211. 10.2337/diabetes.43.2.204, 8288044.
16. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781. 10.1210/en.2006-1168, 17068132.
17. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001, 98:5306-5311. 10.1073/pnas.091021198, 33205, 11309497.
18. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001, 42:1543-1551.
19. Ortmeyer HK, Adall Y, Marciani KR, Katsiaras A, Ryan AS, Bodkin NL, Hansen BC. Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-α agonist (K-111) administration in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1509-R1517.
20. Schäfer SA, Hansen BC, Völkl A, Fahimi HD, Pill J. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)α activator, in non-human primates. Biochem Pharmacol 2004, 68:239-251.
21. Bodkin NL, Pill J, Meyer K, Hansen BC. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res 2003, 35:617-624. 10.1055/s-2003-43510, 14605998.
22. Bénardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Märki HP, Meyer M, Püntener K, Raab S, Ruf A, Schlatter D, Mohr P. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 2009, 19:2468-2473.
23. Pourcet B, Fruchart JC, Staels B, Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006, 11:379-401. 10.1517/14728214.11.3.379, 16939380.
24. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586. 10.1001/jama.294.20.joc50147, 16239637.
25. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol Res 2007, 56:91-98. 10.1016/j.phrs.2007.03.002, 17428674.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
27. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council Guide for the Care and Use of Laboratory Animals 1996, Washington, DC National Academy Press, Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council.
28. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002, 48:171-180.
29. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
30. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003, 115(Suppl 8A):24S-28S. 10.1016/j.amjmed.2003.08.011, 14678862.
31. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462. 10.2337/diabetes.52.2.453, 12540621.
32. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135. 10.1016/S0140-6736(09)60870-9, 19515415.
33. Ortmeyer HK, Sajan MP, Miura A, Kanoh Y, Rivas J, Li Y, Standaert ML, Ryan A, Bodkin NL, Farese RV, Hansen BC. Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: PPARγ agonist improves defective activation of atypical protein kinase C. Antioxid Redox Signal 2011, 14(2):207-19. 10.1089/ars.2010.3234, 20518698.
34. Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL. Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005, 46:1009-1016. 10.1194/jlr.M500002-JLR200, 15716581.
35. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003, 115(Suppl 8A):42S-48S. 10.1016/j.amjmed.2003.09.005, 14678865.
36. Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovas Diabetol 2009, 8:38.